In VOYAGE 1, 837 patients were randomized to placebo (n=174), TREMFYATM 100 mg every 8 weeks (q8w) after Weeks 0 and 4 (n=329), or Humira® (adalimumab) 80 mg at Week 0, 40 mg at Week 1, and 40 mg every 2 weeks thereafter (n=334). Eligible patients (≥18 years of age) had moderate to severe plaque psoriasis (ie, Investigator Global Assessment [IGA] score ≥3, Psoriasis Area and Severity Index [PASI] score ≥12, body surface area [BSA] involvement ≥10%) for at least 6 months and were candidates for systemic therapy or phototherapy. The study comprised a placebo-controlled period (Weeks 0 to 16) after which patients taking placebo crossed over to receive TREMFYATM at Week 16 and 20 and q8w thereafter through Week 48 and an active-comparator–controlled period when TREMFYATM was compared with Humira® from Week 0 through Week 48.1 Please see complete Study Design.
TREMFYATM (guselkumab) is a trademark of Janssen Biotech, Inc. Humira® (adalimumab) is a registered trademark of AbbVie Inc.
Complete the registration form below to receive the latest materials about TREMFYA™ as well as important information to support the treatment of your patients.